Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage
IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
How well does ramucirumab and pembrolizumab work versus standard of care in treating
patients with non-small cell lung cancer that is stage IV or has come back?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and
pembrolizumab work versus standard of care in treating patients with non-small cell
lung cancer that is stage IV or has come back. Immunotherapy with monoclonal antibodies,
such as ramucirumab and pembrolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs
used in standard of care chemotherapy for non-small cell lung cancer, such as docetaxel,
gemcitabine hydrochloride, and pemetrexed, work in different ways to stop the growth
of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving ramucirumab and pembrolizumab together may work
better in treating patients with non-small lung cancer compared to standard of care.
Study Reference #: CLUN19073
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amy Jasek
Phone: (585) 273-1912
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search